Meloxicam clinical effects

Shavlovskaya, О. А.; Бокова, И. А.; Shavlovskiy, N. I.

doi:10.17116/jnevro202212201136

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical, NSAIDs like Naprelan (naproxen sodium), Mobic (meloxicam), and Duexis (ibuprofen and famotidine) inhibit cyclooxygenase (COX) activity, thereby inhibiting prostaglandins (PGs) synthesis and producing antipyretic and analgesic effects used for relief of the symptoms and pain of rheumatoid arthritis. [339][340][341][342][343][344][345] In the case of excessive use or overtime use of NSAIDs, there will be leukopenia, thrombocytopenia, etc., and digestive tract lesions, such as stomach pain, gastric ulcer, and even ulcer bleeding (so famotidine in Duexis is used for inhibition of gastric secretion), liver damage, kidney damage, etc. 346 GCs and Rayos (prednisone) delayed-release tablets also help relieve symptoms and benefit RA patients.…”

Section: Approved Drugsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

show abstract

Section: Approved Drugsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

show abstract

Evaluation of the efficacy and safety of various non-steroidal anti-inflammatory drugs in postmenopausal women with an inflammatory phenotype of osteoarthritis

Shafieva,

Bulgakova,

Shafieva

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are currently the mainstay of the management for relieving pain syndrome in osteoarthritis (OA). NSAIDs are characterized by an individual reaction to medication, as well as a quite high frequency of gastrointestinal side effects. The issue of the disadvantages and advantages of a particular group of NSAIDs is still open.Aim. To evaluate the safety and efficacy of Meloxicam at a dose of 15 mg/day as compared with Nimesulide and placebo in postmenopausal women with an inflammatory phenotype of OA.Results and discussion. The frequency of all adverse events was comparable among the group of patients receiving meloxicam (40.0%), and lower than in the nimesulide group (48.0%), but higher than in the placebo group. A decrease in pain syndrome was observed as early as at 2 weeks of treatment in the group of patients receiving meloxicam. A significant decrease in WOMAC scores (overall result, pain syndrome, stiffness, function) was observed in the group of patients receiving meloxicam, and in the group of patients receiving nimesulide, after 3 weeks of treatment. meloxicam and nimesulide demonstrated high efficacy at 3 weeks compared with the initial VAS scores. The placebo group showed no efficacy.Conclusion. The frequency of all adverse events was lower while taking meloxicam as compared to nimesulide. Our results substantiate the concept to prescribe meloxicam at a dose 15 mg once daily for the treatment of pain and stiffness in post-menopausal women with OA.

show abstract

Meloxicam clinical effects

Cited by 2 publications

References 35 publications

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Evaluation of the efficacy and safety of various non-steroidal anti-inflammatory drugs in postmenopausal women with an inflammatory phenotype of osteoarthritis

Contact Info

Product

Resources

About